Stay updated with breaking news from Selective Targeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, April 24, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells,...
BOSTON, April 08, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced
BOSTON, April 02, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells,...
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...